Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2003 March;49(1) > Minerva Gastroenterologica e Dietologica 2003 March;49(1):53-62





A Journal on Gastroenterology, Nutrition and Dietetics

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index




Minerva Gastroenterologica e Dietologica 2003 March;49(1):53-62

language: English

Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study

Loguercio C., Federico A., De Girolamo V., Ferrieri A., Del Vecchio Blanco C.


Background. Chronic hepatic encephalopathy (HE) represents a frequent and serious complication of chronic liver disease. Aim of the study is to comparatively evaluate the effect of rifaximin, lactitol and their combination in treating chronic HE.
Methods. Forty out-patients (29 males, 11 females, mean age: 59 years, range 40-70), with viral liver cirrhosis and chronic HE (1°-2° degree) were studied. HE was assessed by considering: mental state, asterixis, number connection test (NCT), arterial blood ammonia levels. Patients were randomly assigned to the following treatments: rifaximin (plus sorbitol as placebo) (group R); lactitol (group L); rifaximin plus lactitol (group RL). All treatments were continued for 15 days for 3 cycles, intervalled by 15 days of washout.
Results. The 3 treatments reduced HE, but with different efficacy: patients of group R and RL significantly (p<0.05) documented a faster improvement in HE degree, a higher percentage of patients which normalized mental state and NCT, a faster improve- ment of asterixis and a longer persistence of normal ammonia levels than patients of group L.
Conclusions. Rifaximin in combination with lactitol or sorbitol represents an effective and safe treatment of chronic HE.

top of page

Publication History

Cite this article as

Corresponding author e-mail